Cinitapride monotartrate

Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia[1][2].

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor

Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor

5-HT2 Receptor

5-HT1 Receptor

5-HT4 Receptor

D2 Receptor

Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model[2]. Animal Model: Male Wistar rats with gastric ulceration[2] Dosage: 0.25-1 mg/kg Administration: Intraperitoneal injection; 0.25-1 mg/kg; once Result: Reduced haemorrhagic lesions compared with the ulcerated control group. Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg). Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01). Increased GSH-px activity in the gastric mucosa.

[1]. Du Y, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol. 2014 Apr;48(4):328-35.  

[2]. Alarcón de la Lastra C, et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6.  

[3]. Parthena MARTIN, et al. Compositions and methods for treating seizure disorders. Patent WO2018060732A2.